1. Medtech Insight

TCT 2018: Next-Gen Stents, Key Insights From Leading Experts

 
• By Marion Webb

The Transcatheter Cardiovascular Therapeutics meeting held in San Diego featured late-breaking trials of new stent technologiesincluding TALENT, BIONYX, BIOFLOW-V, SORT-OUT IX, LEADERS FREE II and ReCre8.

San Diego convention center as seen from the Embarcadero South.
The 2018 TCT Conference was held in San Diego, Sept. 21-25. • Source: shutterstock.com

[Editor’s Note:Biotronik announced Nov. 20, 2018 that trial investigators found a statistical calculation error after presenting trial results from the SORT OUT IX data at TCT Congress in September. According to the revised data, Biotronik’s Orsiro drug-eluting stent did not meet non-inferiority criteria as previously reported.]

The Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego featured a series of late-breaking clinical trials including TALENT,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.